University of Louisville

New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four leading inflammasome experts and inventors of IC 100 from University of Miami Miller School of Medicine who have provided ongoing scientific advisory support for IC 100 since its license. WESTON, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces a new SAB to support advancement of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications. Based on its mechanism of action, IC 100, in combination with incretin therapy, is anticipated to augment weight loss, but more importantly, to attenuate the chronic systemic inflammation leading to metabolic complications and other inflammatory comorbidities of obesity. “We are honored to work with such an accomplished and esteemed group of experts,” stated Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO, and President. “Our advisors’ combined expertise and insights in the areas of obesity, metabolic diseases, and inflammasomes will be invaluable as we design IC 100’s clinical development program for obesity and metabolic complications.” Members of ZyVersa’s Obesity, Metabolic and Inflammatory Diseases SAB are listed below. Full biographies are available on ZyVersa's Website. Caroline M. Apovian, MD, FACP, FTOS, DABOM Co-Director, Center for Weight Management and Wellness, Division of Endocrinology, Diabetes, and Hypertension at Brigham and Women’s HospitalProfessor of Medicine, Harvard Medical School Harold Bays, MD, MFOMA, FTOS, FACC, FACE, FNLA, FASPC Medical Director and President, Louisville Metabolic and Atherosclerosis Research CenterClinical Associate Professor, Endocrinology, University of Louisville School of MedicineChief Science Officer of the Obesity Medicine Association Helen Bramlett, PhD Professor, Department of Neurological Surgery, University of Miami Miller School of MedicineThe Miami Project to Cure Paralysis, University of Miami Miller School of Medicine Marc-Andre Cornier, MD Professor of Medicine, Medical University of South CarolinaDirector, Division of Endocrinology, Diabetes and Metabolic Diseases, Medical University of South Carolina Juan Pablo de Rivero Vaccari, PhD Associate Professor, Department of Neurological Surgery, University of Miami Miller School of MedicineThe Miami Project to Cure Paralysis, University of Miami Miller School of MedicineDistinguished Faculty Member, the Center for Cognitive Neuroscience and Aging, University of Miami Miller School of Medicine W. Dalton Dietrich, III, PhD Kinetic Concepts Distinguished Chair in Neurosurgery, and Scientific Director,The Miami Project to Cure Paralysis, University of Miami Miller School of MedicineSenior Associate Dean for Discovery Science and Co-Director, the Institute for Neural Engineering, University of Miami Miller School of MedicineProfessor, Neurological Surgery, Neurology, Biomedical Engineering, and Cell Biology, University of Miami Miller School of Medicine Robert W. Keane, PhD Professor, Physiology and Biophysics, Neurological Surgery and Microbiology, and Immunology, University of Miami Miller School of MedicineThe Miami Project to Cure Paralysis. University of Miami Miller School of Medicine Samuel Klein, MD William H. Danforth Professor of Medicine, Washington University School of MedicineDirector, Center for Human Nutrition, Washington University School of MedicineChief, Division of Nutritional Science and Obesity Medicine, Washington University School of Medicine Suneil Koliwad, MD, PhD Chief, Division of Endocrinology and Metabolism, UCSF HealthGerold Grodsky Professor of Diabetes Research, UCSFMount Zion Health Fund Distinguished Professor of Endocrinology, UCSF About Inflammasome ASC Inhibitor IC 100 IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 was designed to attenuate both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, and Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1β early in the inflammatory cascade. IC 100 also binds to ASC in ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1β and the perpetuation of spread of inflammation that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response. The lead indication for IC 100 is obesity with metabolic complications. To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here. About ZyVersa Therapeutics, Inc. ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody, Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2 Cholesterol Efflux Mediator™ VAR 200. The lead indication for IC 100 is obesity with metabolic complications, and for VAR 200, focal segmental glomerulosclerosis (FSGS). Each therapeutic area offers a “pipeline within a product,” with potential for numerous indications. The total accessible market is over $100 billion. For more information, please visit www.zyversa.com. Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa’s product candidates; ZyVersa’s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa’s ability to protect its intellectual property position; and ZyVersa’s estimates regarding future revenue, expenses, capital requirements and need for additional financing. New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Corporate, Media, and IR Contact:Karen CashmereChief Commercial Officerkcashmere@zyversa.com786-251-9641

Dr. Harkema will spearhead the expansion of transcutaneous and epidural implant spinal stimulation techniques at top centers across the U.S. EAST HANOVER, N.J., Sept. 12, 2024 /PRNewswire/ -- Prominent Neuroscientist Susan Harkema, PhD, will join Kessler Foundation as director of Consortium Growth for Spinal Stimulation in the Tim and Caroline Reynolds Center for Spinal Stimulation on October 1, 2024. She comes to the Foundation after a long, accomplished career at the University of Louisville, KY. Continue Reading Neuroscientist Susan Harkema, PhD, joins Kessler Foundation's Tim and Caroline Reynolds Center for Spinal Stimulation Post this Prominent neuroscientist Susan Harkema, PhD, will join Kessler Foundation in October 2024 as director of Consortium Growth for Spinal Stimulation in the Tim and Caroline Reynolds Center for Spinal Stimulation. In her newly created position, Dr. Harkema will concentrate on developing and expanding the research implementation of both transcutaneous and epidural implant stimulation at centers in the U.S. and internationally. She will report directly to the Foundation's Chief Medical Officer Steven Kirshblum, MD, and indirectly to Gail Forrest, PhD, director of the Reynolds Center for Spinal Stimulation and associate director of the Center for Mobility and Rehabilitation Engineering Research . Dr. Harkema is nationally recognized for her research in the field of spinal cord injury, neural plasticity, and neuromodulation. She held the position of professor in the Departments of Neurology and Neurosurgery at the University of Louisville for more than 20 years. She also held the Owsley B. Frazier Rehabilitation Chair in Neurological Rehabilitation and associate director of the Kentucky Spinal Cord Injury Research Center where she led the Pediatric NeuroRecovery, Adult NeuroRecovery, and Epidural Stimulation programs. Under her leadership over the past decade, these programs have collectively been awarded over $70 million in grants for spinal cord injury research. During that same timeframe, she also led six rehabilitation centers and nine community fitness and wellness centers in the translation of scientific knowledge into clinical practice as the director of the Christopher and Dana Reeve Foundation NeuroRecovery Network. "I'm looking forward to joining forces with Kessler Foundation because it offers an unparalleled opportunity to collaborate with some of the brightest minds and push the boundaries of innovation in spinal cord injury research," said Dr. Harkema. "Joining this esteemed organization allows me to contribute my knowledge while being part of a team that is at the forefront of groundbreaking developments. The Foundation represents a unique chance to continue growing professionally and make a significant impact in an environment that values excellence and forward-thinking," she explained. Dr. Harkema's studies concentrate on understanding how the spinal cord can adapt and reorganize itself in response to injury and interventions, which has significant implications for developing novel therapies to promote recovery led by advancements in epidural stimulation. "Dr. Harkema's research focuses on neural plasticity of spinal networks and recovery of function after spinal cord injury, which complements the work conducted by Foundation scientists on control and modulation of motor and sensory functions. With her knowledge, experience, and drive, our team is poised for unrivaled success," asserted Dr. Kirshblum. He also serves as co-director of the Reynolds Center and the Center for Spinal Cord Injury Research at the Foundation. Among her notable achievements is the discovery of the role neuromodulation and rehabilitation strategies play in restoring motor and autonomic functions in individuals living with spinal cord injury. Her recent studies have demonstrated that adults and children living with chronic paralysis can recover voluntary leg movement, stand independently, and improve cardiovascular and bladder function through epidural stimulation. These findings have expanded translational research, driving efforts to enhance the design and functionality of implantable epidural stimulators. Dr. Harkema has published more than 110 scholarly manuscripts and book chapters; delivered over 100 worldwide lectures and keynotes; and sat on numerous advisory boards and review panels. She earned her Bachelor of Science and PhD degrees in physiology at Michigan State University and conducted her postdoctoral fellowship in neurology at the University of California, Los Angeles (UCLA). After joining the faculty at UCLA in 1995 as an assistant researcher, Dr. Harkema became an assistant professor in the Department of Neurology and the Brain Research Institute. "We welcome the renowned Dr. Susan Harkema, whose expertise will undoubtedly strengthen our research efforts and help us push the boundaries of what's possible in the field of spinal cord research," affirmed Rodger DeRose, president and CEO of the Foundation. "Having Susie join our team is a significant boost to our research initiatives, and will allow us to explore new avenues and accelerate the progress of our work," he added. "I've had the privilege of working with Dr. Harkema over the last 15 years on numerous interventions, clinical trials, and collaborative research initiatives. I'm thrilled that she will be joining our team to help fulfill the goal of the Reynolds Center to extend both transcutaneous and epidural implant stimulation to other prominent centers throughout the U.S.," said Dr. Forrest, adding, "We are confident that Dr. Harkema will provide invaluable insights, accelerating our research and development efforts to deliver cutting-edge solutions." About Kessler Foundation Kessler Foundation, a major nonprofit organization in the field of disability, is a global leader in rehabilitation research. Our scientists seek to improve cognition, mobility, and long-term outcomes, including employment, for adults and children with neurological and developmental disabilities of the brain and spinal cord including traumatic brain injury, spinal cord injury, stroke, multiple sclerosis, and autism. Kessler Foundation also leads the nation in funding innovative programs that expand opportunities for employment for people with disabilities. For more information, visit KesslerFoundation.org. Stay Connected with Kessler Foundation X (formerly known as Twitter) | Facebook | YouTube | Instagram | SoundCloud SOURCE Kessler Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

WEDNESDAY, Aug. 28, 2024 -- The trees and shrubs in your neighborhood could be giving you a big health boost, a new study finds. People have lower levels of inflammation in neighborhoods where the number of trees and shrubs is more than doubled compared to other nearby locales, University of Louisville researchers reported this week at the International Society for Environmental Epidemiology annual meeting in Santiago, Chile. “Trees are beautiful, but these results show that the trees around us are also beneficial to individual and community health,” said University of Louisville President Kim Schatzel . For the study, researchers added more than 8,000 large trees and shrubs to some neighborhoods in Louisville, Ken., but not others. The plantings occurred from 2019 through 2022 within a four-square-mile section of south Louisville, in low- to middle-income neighborhoods. The team then compared 745 residents’ health data, to see how more greenery might have improved their overall well-being. Results show that residents in the greener neighborhoods had 13% to 20% lower levels of a biomarker associated with inflammation called high-sensitivity C-reactive protein (hsCRP). Higher levels of this marker are strongly associated with heart risks, and can be an even stronger indicator of an impending heart attack than cholesterol levels, researchers noted. It also indicated a higher risk of diabetes and some cancers. The reduction in hsCRP found in greener neighborhoods corresponds to a 10% to 15 lower risk of heart attack, cancer or death from any disease, researchers added. “Trees contribute more to our lives than beauty and shade. They can improve the health of the people living around them,” said senior researcher Aruni Bhatnagar , a professor of medicine with the University of Louisville. “Although several previous studies have found an association between living in areas of high surrounding greenness and health, this is the first study to show that a deliberate increase in greenness in the neighborhood can improve health,” Bhatnagar added in a university news release. “This finding will bolster the push to increase urban greenspaces.” Because these findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.